| scholarly article | Q13442814 |
| P50 | author | Andreas Schneeweiss | Q37074948 |
| Michael P. Lux | Q37372079 | ||
| Peter A. Fasching | Q64005064 | ||
| P2093 | author name string | Volkmar Müller | |
| Johannes Ettl | |||
| Achim Wöckel | |||
| Hans Tesch | |||
| Wolfgang Janni | |||
| Diana Lüftner | |||
| Andreas D Hartkopf | |||
| Tanja N Fehm | |||
| Florin-Andrei Taran | |||
| Florian Schütz | |||
| Erik Belleville | |||
| Friedrich Overkamp | |||
| Hans-Christian Kolberg | |||
| Naiba Nabieva | |||
| P2860 | cites work | Genome-wide association studies identify four ER negative-specific breast cancer risk loci | Q24622610 |
| Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial | Q28305038 | ||
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
| Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | Q29417100 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials | Q30982699 | ||
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial | Q33415041 | ||
| Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment | Q34074094 | ||
| Breast-cancer risk in families with mutations in PALB2 | Q34148873 | ||
| Breast Cancer Risk - Genes, Environment and Clinics | Q34201805 | ||
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials | Q34486930 | ||
| Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer | Q34996647 | ||
| Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies | Q35022847 | ||
| Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network | Q35054455 | ||
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population | Q35089479 | ||
| Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium | Q35119701 | ||
| Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium | Q35532898 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer | Q35755874 | ||
| 19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
| Common breast cancer susceptibility loci are associated with triple-negative breast cancer | Q35891162 | ||
| Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Q35996692 | ||
| Bevacizumab added to neoadjuvant chemotherapy for breast cancer | Q36106083 | ||
| The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
| Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial | Q36219254 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk | Q36600605 | ||
| Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers | Q36742577 | ||
| Genome-wide association analysis identifies three new breast cancer susceptibility loci | Q36842233 | ||
| tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation | Q36858215 | ||
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Q36897003 | ||
| Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial | Q37132369 | ||
| Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. | Q37300024 | ||
| Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade | Q37385681 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Pathological complete response in neoadjuvant treatment of breast cancer | Q38366388 | ||
| Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial | Q38373098 | ||
| COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy | Q38439080 | ||
| Extended anti-HER2 therapy in early breast cancer: longer beats shorter? | Q38811193 | ||
| Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy | Q40178893 | ||
| Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial | Q40914660 | ||
| Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods | Q41011976 | ||
| Neoadjuvant Treatment of Breast Cancer - Advances and Limitations | Q42363504 | ||
| Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients | Q43927056 | ||
| Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis | Q44896647 | ||
| Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study | Q45330030 | ||
| Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Q46103372 | ||
| Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients | Q46494349 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium | Q47190168 | ||
| Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results | Q47788774 | ||
| Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. | Q48361014 | ||
| The Shift From Sentinel Lymph Node Biopsy Performed Either Before or After Neoadjuvant Systemic Therapy in the Clinical Negative Nodes of Breast Cancer Patients. Results, and the Advantages and Disadvantages of Both Procedures. | Q50066585 | ||
| Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. | Q50089754 | ||
| Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. | Q51764547 | ||
| Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. | Q52572827 | ||
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | Q52893849 | ||
| PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar | Q52897434 | ||
| PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin | Q52897474 | ||
| Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 | Q54409668 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. | Q54950358 | ||
| Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer etc. | Q56967384 | ||
| BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study | Q56968709 | ||
| Opportunities and priorities for breast surgical research | Q57299103 | ||
| Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis | Q57461653 | ||
| Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST) | Q57461922 | ||
| BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients | Q57990746 | ||
| Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer | Q58101133 | ||
| Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea | Q58124814 | ||
| Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto | Q58592505 | ||
| Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria | Q58695244 | ||
| Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | Q58797082 | ||
| Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Adva | Q60050114 | ||
| Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | Q60683126 | ||
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 | ||
| Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | Q62583133 | ||
| The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast | Q86050224 | ||
| Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: An evaluation of 8323 patients | Q88484370 | ||
| The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer | Q89305074 | ||
| Translational highlights in breast cancer research and treatment: recent developments with clinical impact | Q90301915 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adjuvant therapy | Q2481887 |
| Early breast cancer | Q57142283 | ||
| P304 | page(s) | 256-267 | |
| P577 | publication date | 2019-03-01 | |
| P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
| P1476 | title | Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer | |
| P478 | volume | 79 |
Search more.